This raised the possibility that short-term pharmacological CaMKII inhibition could also affect memory, which would be a counter-indication for promising neuroprotective treatment of cerebral ischemia with the CaMKII inhibitor tatCN19o (18, 19). The gene discussed is CAMK2G; the disease is Cerebral ischemia.